Mbabane – The Government of the Kingdom of Eswatini, in collaboration with the U.S. through the President’s Emergency Plan for AIDS Relief (PEPFAR), the Global Fund, and California-based Gilead Sciences, has officially launched a groundbreaking HIV prevention initiative introducing long-acting injectable lenacapavir.
The program, announced on Tuesday, brings the U.S.-developed medication to Eswatini, giving emaSwati access to the same class-leading HIV prevention drug recently made available in North America and Europe.
Chargé d’Affaires at the U.S. Embassy in Eswatini, Marc Weinstock, said the project aims to ensure that the intervention is implemented swiftly, affordably, and with maximum impact. 
